PuraPharm (HKSE:01498) Debt-to-EBITDA

: -8.66 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

PuraPharm's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$322.0 Mil. PuraPharm's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$102.8 Mil. PuraPharm's annualized EBITDA for the quarter that ended in Dec. 2023 was HK$-49.1 Mil. PuraPharm's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -8.66.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for PuraPharm's Debt-to-EBITDA or its related term are showing as below:

HKSE:01498' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -16.14 Med: 2.31 Max: 10.03
Current: -16.14

During the past 10 years, the highest Debt-to-EBITDA Ratio of PuraPharm was 10.03. The lowest was -16.14. And the median was 2.31.

HKSE:01498's Debt-to-EBITDA is ranked worse than
100% of 657 companies
in the Drug Manufacturers industry
Industry Median: 1.66 vs HKSE:01498: -16.14

PuraPharm Debt-to-EBITDA Historical Data

The historical data trend for PuraPharm's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PuraPharm Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

-4.43

4.57

-13.29

-10.86

-16.14

PuraPharm Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-EBITDA																-2.68	29.98	-4.66	-127.62	-8.66

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, PuraPharm's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PuraPharm Debt-to-EBITDA Distribution

For the Drug Manufacturers industry and Healthcare sector, PuraPharm's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where PuraPharm's Debt-to-EBITDA falls into.

PuraPharm Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

PuraPharm's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(321.995	+	102.775)	/	-26.314
	=	-16.14

PuraPharm's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(321.995	+	102.775)	/	-49.064
	=	-8.66

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.

PuraPharm (HKSE:01498) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

PuraPharm Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of PuraPharm's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

PuraPharm (HKSE:01498) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PuraPharm Corporation Ltd (HKSE:01498) » Definitions » Debt-to-EBITDA

Traded in Other Exchanges

N/A

Address

Wireless Centre, Phase One, Unit 201-207, 2nd Floor, Hong Kong Science Park, Tai Po, New Territories, Hong Kong, HKG

Website

https://www.purapharm.com

PuraPharm Corporation Ltd is a Hong Kong-based Chinese medicine Company. It is engaged in the research and development, production, marketing and sale of concentrated Chinese medicine granules (CCMG) products marketed under the brand Nong's. In addition, the organization is engaged in rendering Chinese medical diagnostic services. The operating segments of the group are China CCMG, Hong Kong CCMG, Chinese healthcare products, Plantation and Clinics. It generates maximum revenue from the China CCMG segment mainly engages in the production and sale of CCMG products in China. The group derives revenue from the customers located in Hong Kong, Mainland China and Other countries.

PuraPharm (HKSE:01498) Headlines

No Headlines